

1
2
3 1 **Title:** Disability-Free Survival after Major Cardiac Surgery in a Population-Based Cohort
4
5
6 2

7
8 3 **Authors:** Louise Y. Sun, MD, SM; Anan Bader Eddeen, MSc; Thierry G. Mesana, MD, PhD
9

10 4 **Affiliations:** From the Division of Cardiac Anesthesiology, Department of Anesthesiology and
11
12 5 Pain Medicine, University of Ottawa Heart Institute, Ontario, Canada (LYS); the School of
13
14 6 Epidemiology and Public Health, University of Ottawa, Ontario, Canada (LYS); the Institute for
15
16 7 Clinical Evaluative Sciences, Ontario, Canada (LYS, ABE); the Division of Cardiac Surgery,
17
18 8 Department of Surgery, University of Ottawa Heart Institute, Ontario, Canada (TGM).
19
20
21

22
23 9 **Address for Correspondence and Reprints:**

24
25 10 Louise Y. Sun, MD, SM, FRCPC, FAHA
26
27 11 Room H2410, 40 Ruskin Street
28
29 12 Ottawa, ON K1Y 4W7
30
31 13 Phone: 1 613 696 7381 Fax: 1 613 696 7099
32
33 14 Email: lsun@ottawaheart.ca
34
35
36
37
38

39 16 **Sources of Support:** We acknowledge support from an operating grant from the Canadian
40
41 17 Institutes of Health Research (Grant #4752). Dr. Sun is supported by the Ottawa Heart Institute
42
43 18 Research Corporation. The funders do not have a role in the design and conduct of the study, in
44
45 19 the collection, analysis, and interpretation of the data, nor in the preparation, review, or approval
46
47 20 of the manuscript.
48
49

50 21 **Disclosures:** None
51
52
53
54

55 23 **Running Title:** Disability-free survival after heart surgery
56
57
58
59
60

1
2
3 **1 ABSTRACT**
4

5 **2 Background:** Cardiovascular research has been dedicated to “tombstone” outcomes such as
6
7
8 **3** death and complications, with little attention paid to outcomes that may also be important from a
9
10 **4** patient’s perspective. We examined the rates of disability-free survival as a novel, patient-
11
12
13 **5** defined outcome after cardiac surgery.

14 **6 Methods:** This was a retrospective cohort study of patients ≥ 40 years of age who underwent
15
16
17 **7** coronary artery bypass grafting (CABG) and/or aortic, mitral, tricuspid valve surgery in Ontario
18
19 **8** between October 1 2008-December 31 2016. The primary outcome was disability (composite of
20
21
22 **9** stroke, ≥ 3 non-elective hospitalizations and long-term care admission) within one year after
23
24 **10** surgery. The procedure-specific risk of disability was assessed using a multivariable Fine and
25
26 **11** Gray subdistribution hazards model with death as a competing risk.

27
28 **12 Results:** Of 72,824 patients, 2,431 (4.6%) developed disability in the year after CABG, 677
29
30
31 **13** (6.5%) after single valve, 118 (9.0%) after multiple valves, 718 (9.0%) after CABG/single valve,
32
33 **14** and 87 (13.1%) after CABG/multiple valve surgery. With isolated CABG as the reference group,
34
35 **15** the adjusted HRs for disability were 1.34 (95% CI: 1.21-1.48) after single valve, 1.43 (1.18-1.75)
36
37 **16** after multiple valves, 1.38 (1.26-1.51) after CABG/single valve, and 1.78 (1.43-2.23) after
38
39 **17** CABG/multiple valve surgery. Combined CABG/multiple valve surgery, heart failure, creatinine
40
41
42 **18** ≥ 180 $\mu\text{mol/L}$, alcoholism, dementia and depression were independent disability risk factors.

43
44 **19 Interpretation:** We found that the cumulative incidence of disability was lowest after isolated
45
46
47 **20** CABG and highest after combined CABG/multiple valve reconstruction. Our findings point to a
48
49 **21** need for personalized disability risk prediction models to better enable patient-centered care.
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION

2 Cardiac surgery is a growing field, with two million procedures currently being performed
3 globally each year.¹ The last two decades have seen important advances in surgical and
4 perioperative care, as well as improved patient survival.²⁻⁴ On the other hand, as patients
5 presenting for surgery become increasingly elderly and frail, they shift their goals and priorities
6 towards how surgery might affect personal freedom and mobility, rather than to provide
7 longevity alone.⁵⁻⁹ New or residual impairments after surgery are of particular concern to patients
8 and clinicians alike, but the quality and standard of cardiac care long has been assessed by
9 traditional “tombstone” measures such as mortality and major adverse cardiovascular events
10 (MACE).^{5, 8, 10-12} Indeed, patient-centered care represents a priority area for modern medical
11 practice and research, and the facilitation of shared surgical decision making could be improved
12 by incorporating patient perspectives and patient-derived data.¹³⁻¹⁵

13 Our group has recently derived “disability-free survival” as a novel, patient-defined
14 outcome through a large-scale survey of > 3000 patients with cardiovascular diseases.¹⁶
15 According to patient preferences and values, disability was defined as the composite of stroke,
16 recurrent non-elective hospitalizations and nursing home admission.¹⁶ Before this outcome
17 measure could be meaningfully utilized to inform patient-centered decision-making, its
18 epidemiology and impact need to first be described at the population level. We therefore
19 conducted the current study to examine the rates of disability-free survival after major cardiac
20 surgery in a population-based cohort.

21

1
2
3 **1 METHODS**

4
5 **2 *Design and Study Population***

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3 We conducted a population-based, retrospective cohort study in Ontario, Canada. The use
4 of data in this project was authorized under section 45 of Ontario's *Personal Health Information*
5 *Protection Act*, which does not require review by a Research Ethics Board.¹⁷

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

6 Included were adult Ontario residents 40 years of age or older, who underwent CABG,
7 and/or aortic, mitral or tricuspid valve surgery between October 1, 2008 and December 31, 2016.
8 For those patients who underwent multiple cardiac procedures during the study period, the first
9 procedure was considered the index procedure. Exclusion criteria were non-Ontario residency
10 status, those with missing information regarding age and sex, and those who had concomitant
11 arrhythmia, pulmonic valve or thoracic aorta surgery. A flow diagram detailing the process used
12 to select the study cohort is shown in Supplemental Figure 1. During the study period, Ontario
13 was Canada's most populous province with a publicly funded, universal health care system that
14 reimbursed all covered services and providers.

15
16 **16 *Data Sources***

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

17 We used the administrative healthcare databases from the Institute for Clinical Evaluative
18 Sciences (ICES) with information on all Ontario residents, and the detailed clinical registry data
19 from CorHealth Ontario. CorHealth Ontario maintains a prospective registry of all patients who
20 undergo invasive cardiac procedures in Ontario. All 20 advanced cardiac hospitals in Ontario
21 participate in the registry. It captures demographic, comorbidity and procedural-related
22 information and has been validated through selected chart audits. In addition, CorHealth Ontario
23 ejection fraction and angiographic data undergo core laboratory validation.¹⁸

1
2
3 1 Individuals who underwent the specified cardiac procedures were identified from the
4
5 2 CorHealth Ontario registry, and linked deterministically to the ICES administrative databases by
6
7 3 using encrypted unique confidential codes. Specifically, the date and type of cardiac procedures,
8
9 4 physiologic and comorbidity data from CorHealth Ontario were linked with the Canadian
10
11 5 Institute for Health Information's Discharge Abstract Database (DAD; comorbidities and
12
13 6 hospital admissions) and Same Day Surgery (SDS) database (comorbidities), the Ontario Health
14
15 7 Insurance Plan (OHIP) database (physician service claims), the Registered Persons Database
16
17 8 (RPDB; ascertainment of vital statistics), the Continuing Care Reporting System (CCRS;
18
19 9 admissions to long-term care facilities) and Canadian census. These administrative databases
20
21 10 have been validated for many outcomes, exposures, and comorbidities, including heart failure
22
23 11 (HF), chronic obstructive pulmonary disease (COPD), asthma, hypertension, myocardial
24
25 12 infarction (MI) and diabetes.¹⁹⁻²²

13 14 ***Comorbidities***

15 Comorbidities were identified from the CorHealth Ontario registry and supplemented
16
17 16 with data from DAD, SDS and OHIP using International Classification of Diseases 10th Revision
18
19 17 (ICD-10-CA) codes²³ within five years prior to the index procedure, according to validated
20
21 18 algorithms.^{19,21,24,24,25, 26} We estimated socioeconomic status based on patients' neighborhood
22
23 19 median income in the Canadian census, and determined their residence (rural versus urban) using
24
25 20 the definitions from Statistics Canada.²⁷ Procedural urgency was ascertained from the CorHealth
26
27 21 Ontario registry. Height, weight and body mass index (BMI) were identified from the CorHealth
28
29 22 Ontario registry, and used to define morbid obesity (weight >159 kg or BMI \geq 40 kg/m²).^{16, 26, 28,}
30
31 23 ²⁹ Frailty status was identified using the Johns Hopkins Adjusted Clinical Groups frailty-defining

1 diagnoses indicator, which is an instrument designed and validated for research of frailty-related
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 diagnoses indicator, which is an instrument designed and validated for research of frailty-related
2 outcomes and resource utilization using administrative data.²⁹⁻³⁴

4 ***Outcomes***

5 The primary outcome was disability, defined as patient-derived composite of stroke,
6 nursing home admission, and recurrent non-elective hospital admissions of ≥ 3 episodes
7 occurring within 1 year of surgery. Secondary outcomes consisted of all-cause death and each
8 individual component of disability. Stroke requiring hospitalization was identified using a
9 validated algorithm with 70% sensitivity and 99% specificity.³⁵ Non-elective hospital admissions
10 were ascertained by using the DAD, and long-term care admissions were ascertained using the
11 CCRS.

13 ***Statistical Analysis***

14 Continuous variables are expressed as mean (standard deviation) and categorical
15 variables as number (proportions). Outcomes were assessed through December 31, 2017.
16 Patients were censored when they lost possession of a valid Ontario health insurance card.
17 Disability-free survival was defined as survival time from the date of index surgery until the date
18 of a disability-defining event, death or last follow-up, whichever occurred earlier. For patients
19 experiencing recurrent non-elective hospitalizations, disability was considered to occur on the
20 date of the first admission. To account for death as a competing risk, we estimated the
21 cumulative incidence of disability over time using Cumulative Incidence Functions (CIFs), and
22 the risk of disability and each of the disability-defining events with multivariable Fine and Gray
23 subdistribution hazards models using the variables listed in Table 3. We explored whether sex

1 had a modifying effect on the relationship between disability and type of surgery, by using a
2 multiplicative interaction term of sex*type of surgery within each of the multivariable time-to-
3 event models.

4 Analyses were performed using SAS 9.4 (SAS Institute, Cary, NC), with statistical
5 significance defined by a two-sided P-value of < 0.05 . We used the adjusted hazard ratio (HR)
6 and associated 95% confidence intervals (CI) to describe the measure of association, and defined
7 a clinically meaningful effect as $HR \geq 1.50$.

Confidential

1 RESULTS

2 *Baseline Characteristics*

3 A total of 72,824 patients were included in the study. The baseline patient characteristics
4 according to type of surgery are summarized in Table 1. Isolated CABG accounted for 72% of
5 the provincial procedure volume. These were most likely to be performed in younger men with a
6 history of previous MI and PCI; and least likely to be performed in those with HF. Compared to
7 those who underwent combined CABG/valve procedures, those who underwent isolated valve
8 surgery were younger and were more likely to have preserved LVEF and a lower burden of
9 comorbidities as evidenced by a lower Charlson comorbidity index. Further, those who
10 underwent combined CABG/multiple valve surgery were amongst the frailest and burdened with
11 the highest number of comorbidities.

13 *Effect Modification by Sex*

14 As we did not observe a statistically significant interaction effect between sex and type of
15 surgery (interaction $p = 0.07$), subsequent analyses were not stratified by sex.

17 *Disability-Free Survival*

18 Table 2 summarizes the rates of disability, death and individual disability-defining events
19 according to surgery type. Figure 1 illustrates the cumulative incidence of disability, and Figure
20 2 the estimated survival at one-year. The incidence proportions of disability and death were as
21 follows: 2,431 (4.6%) vs. 1,839 (3.5%) in the CABG-only group; 677 (6.5%) vs. 540 (5.2%) in
22 the single valve group; 118 (9.0%) vs. (10.7%) in the multiple valves group; 718 (9.0%) vs. 734
23 (9.2%) in the CABG/single valve group; and 87 (13.1%) vs. 94 (14.1%) in the CABG/multiple

1 valves group. Overall, the one-year cumulative incidence of disability was lowest in patients who
2 underwent isolated CABG and highest after CABG/multiple valve surgery. Disability occurred
3 more frequently than death in the year after isolated CABG and single valve surgery.

4 5 ***Disability-Defining Events***

6 The cumulative incidence of stroke, recurrent non-elective hospitalizations and long-term
7 care admissions varied by type of surgery (Table 1 and Supplemental Figures 2-4). Specifically,
8 the rates of all three events were lowest after isolated CABG, highest after combined
9 CABG/multiple valve reconstruction, and were similar after multiple valve and CABG/single
10 valve surgery.

11 12 ***Disability Risk Factors***

13 The multivariable predictors of disability are summarized in Table 3. With isolated CABG
14 as the reference group, the adjusted subdistribution HRs for disability were 1.34 (95% CI, 1.21-
15 1.48) for single valve, 1.43 (1.18-1.75) for multiple valves, 1.38 (1.26-1.51) for CABG/single
16 valve and 1.78 (1.43-2.23) for CABG/multiple valve reconstruction. Other statistically
17 significant risk factors of disability were age, female sex, emergent operative status, low income,
18 a history of hypertension, atrial fibrillation, MI, HF, cerebrovascular disease, peripheral arterial
19 disease, current smoker, COPD, diabetes, anemia, renal insufficiency, liver disease, alcoholism,
20 dementia, depression, and cancer. Of these, CABG/multiple valve surgery, HF, baseline
21 creatinine ≥ 180 $\mu\text{mol/L}$, alcoholism, dementia and depression were the most clinically
22 significant predictors of disability.

1 INTERPRETATION

2 To our knowledge, this is the first population-based study to systematically describe the
3 incidence and risk factors of patient-defined disability after common cardiac procedures. We
4 found that: 1) the cumulative incidence of disability was lowest after isolated CABG and highest
5 after CABG/multiple valve surgery. 2) Disability occurred more frequently than death in the year
6 after isolated CABG and single valve surgery. 3) Combined CABG/multiple valve surgery, HF,
7 baseline creatinine $\geq 180 \mu\text{mol/L}$, alcoholism, dementia and depression were important
8 predictors of disability in the year after cardiac surgery.

9 10 *The Need for Patient-Defined Outcomes in Cardiovascular Research*

11 Traditional revascularization trials have sometimes been referred to as “tombstone trials”⁶
12 due to their focus on death and complications. However, a survey of cardiovascular patients
13 indicated that important outcomes identified by patients were in fact very different compared to
14 those from the clinician’s view.¹⁶ Indeed, the incorporation of patient perceptions and values into
15 the design of outcome measures has been proposed as a priority area for cardiovascular research.
16 Such a paradigm shift has been shown to increase the relevance of the research to the end user,
17 speed up the uptake of research into practice, and empower patients to make better informed
18 decisions.³⁶

19 To date, few studies have directly engaged surgical patients to determine what outcomes
20 were meaningful to them as important end users of the research. Such studies include surveys of
21 noncardiac surgery patients to rank outcomes such as postoperative nausea, vomiting, pain and
22 somnolence in order of unpleasantness,³⁷⁻³⁹ but similar research has not been conducted in the
23 realm of cardiac surgery. “Patient-centered” cardiac surgery research has instead employed

1 standard, clinician-derived instruments (e.g., Seattle Angina Questionnaire, Rose Dyspnea Score,
2 and Patient Health Questionnaire) that were based on expert consensus alone without active
3 input from patients.⁴⁰ These standard instruments may not be meaningful to all patients as they
4 do not capture all relevant aspects of outcomes after treatment.⁴¹ Outcomes are an important
5 determinant of treatment satisfaction, and the use of patient-defined outcomes has the unique
6 advantage of improving both patient satisfaction and adherence to treatment.

7 There is no universal agreement on the definition of disability in cardiovascular research.¹¹
8 Prospective studies using clinician-derived instruments are often limited by small sample size
9 and short follow-up durations within a single center setting. In the present study, we used a novel
10 and versatile definition of disability based on patient preferences, which is adaptable to both
11 prospective trials and large retrospective cohorts. Knowledge generated from this broad
12 epidemiologic study will inform areas of focus for practice-changing research in the future.

14 ***Disability After Cardiac Surgery***

15 CABG is an advancing field where operative mortality has steadily declined over the
16 years.⁴² This, together with the younger age of presentation for CABG, could explain the lower
17 observed rates of disability after this procedure as compared to complex CABG/multiple valve
18 procedures, which are often performed on older and frailer patients. Complex surgery is
19 associated with greater physiologic stresses such as fluid and electrolyte shifts, prolonged bypass
20 durations, and a higher likelihood of exposure to low cardiac output, hypotension, end organ
21 injury and death.⁴³

22 To date, disability after cardiac surgery has been reported in the form of health-related
23 quality of life (QoL), using instruments such as the SF-36, in several small observational studies.

1
2
3 1 In a single center study of 112 patients, patients reported higher than normative scores in
4
5 2 subscales of social functioning, role physical and role emotional; and lower scores in physical
6
7 3 function, bodily pain, general health, vitality social function and mental health; at one year after
8
9 4 CABG.⁴⁴ In a study of 534 consecutive cardiac surgery patients over the age of 75 years, mean
10
11 5 reported QoL improved at 6 months postoperatively as compared to baseline.⁴⁵ In a study of 154
12
13 6 nonagenarians who underwent CABG and/or valve procedures, 83% of the survivors reported an
14
15 7 improvement in QoL and 4% a decline in QoL, one year after surgery.⁴⁶ Our findings
16
17 8 demonstrate that the incidence of patient-defined disability may in fact be greater than previously
18
19 9 described by traditional instruments. Moreover, we were able to describe the population-based
20
21 10 incidence of disability by type of surgery and across a wider patient age range. We found that the
22
23 11 burden of disability was higher than death after routine procedures such as isolated CABG and
24
25 12 single valve surgery, and these findings were driven mostly by recurrent hospital admissions,
26
27 13 followed by stroke, especially in those with HF, renal dysfunction, alcoholism, dementia and
28
29 14 depression. As patients' ability to make informed decisions is often influenced by the emotional
30
31 15 and logistical repercussions of their disease diagnosis as well as limitations in health literacy,
32
33 16 patients with these high-risk features should be the focus of informed perioperative counseling
34
35 17 and undergo formal heart team evaluation regarding the risks and benefits of alternative
36
37 18 treatment strategies.
38
39
40
41
42
43
44
45
46

47 ***Limitations***

48
49 21 This study has several limitations. *Firstly*, data pertaining to stroke severity is unavailable
50
51 22 in the databases used. As some stroke patients experience full functional recovery, our findings
52
53 23 may have over-estimated the burden of stroke-related disability. *Secondly*, our definition of
54
55
56
57
58
59
60

1 disability was based solely on patient perceptions and values. Further studies could aim to
2 additionally elicit feedback from family members and caregivers to co-define outcomes, with
3 input and guidance from clinicians. *Lastly*, cohort studies are by nature subjected to residual
4 confounding.

6 **CONCLUSIONS**

7 We studied the procedure-specific incidence of a patient-defined disability outcome in a
8 large cohort of cardiac surgical patients. We found disability to be a more frequent complication
9 than death in the year after isolated CABG and single valve surgeries. In addition, patients who
10 undergo combined CABG/multiple valve surgery, and those who have a history of HF, baseline
11 creatinine ≥ 180 $\mu\text{mol/L}$, alcoholism, dementia and depression are at the greatest risk for
12 developing disability. Future research should be dedicated to personalized disability risk
13 prediction to better inform the joint therapeutic decision-making process and in doing so, to
14 improve the efficiency and effectiveness of health care delivery as well as patient satisfaction.

1
2
3 1 **Acknowledgements:** This study is supported by the Institute for Clinical Evaluative Sciences
4
5 2 (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term
6
7 3 Care (MOHLTC). The authors acknowledge that the clinical registry data used in this analysis is
8
9 4 from participating hospitals through CorHealth Ontario, which serves as an advisory body to the
10
11 5 MOHLTC, is funded by the MOHLTC, and is dedicated to improving the quality, efficiency,
12
13 6 access and equity in the delivery of the continuum of adult cardiac and stroke care in Ontario,
14
15 7 Canada. The authors also acknowledge the usage of data compiled and provided by the Canadian
16
17 8 Institute for Health Information. These datasets were linked using unique encoded identifiers and
18
19 9 analyzed at ICES. The analyses, conclusions, opinions and statements expressed in the
20
21 10 manuscript are those of the authors, and do not necessarily reflect those of the above agencies.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3 **1 REFERENCES**
4

- 5
6 2 1. Kang HC and Chung MY. Images in clinical medicine. Peripheral artery disease. *The*
7 3 *New England journal of medicine*. 2007;357:e19.
8 4 2. Favaloro RG. Critical Analysis of Coronary Artery Bypass Graft Surgery: A 30-Year
9 5 Journey. *Journal of the American College of Cardiology*. 1998;31:1B-63B.
10 6 3. Karim MN, Reid CM, Huq M, Brilleman SL, Cochrane A, Tran L and Billah B.
11 7 Predicting long-term survival after coronary artery bypass graft surgery. *Interactive*
12 8 *Cardiovascular and Thoracic Surgery*. 2018;26:257-263.
13 9 4. Baillot RG, Joannisse DR, Stevens LM, Doyle DP, Dionne B and Lellouche F. Recent
14 10 evolution in demographic and clinical characteristics and in-hospital morbidity in patients
15 11 undergoing coronary surgery. *Canadian journal of surgery Journal canadien de chirurgie*.
16 12 2009;52:394-400.
17 13 5. Myles PS. Meaningful outcome measures in cardiac surgery. *J Extra Corpor Technol*.
18 14 2014;46:23-7.
19 15 6. Chalmers I and Clarke M. Outcomes that matter to patients in tombstone trials. *Lancet*.
20 16 2001;358:1649.
21 17 7. Selby JV, Beal AC and Frank L. The Patient-Centered Outcomes Research Institute
22 18 (PCORI) national priorities for research and initial research agenda. *Jama*. 2012;307:1583-4.
23 19 8. Rahimi K, Malhotra A, Banning AP and Jenkinson C. Outcome selection and role of
24 20 patient reported outcomes in contemporary cardiovascular trials: systematic review. *BMJ*.
25 21 2010;341:c5707.
26 22 9. Mulley AG. Inconvenient truths about supplier induced demand and unwarranted
27 23 variation in medical practice. *BMJ*. 2009;339:b4073.
28 24 10. Caine N, Harrison SC, Sharples LD and Wallwork J. Prospective study of quality of life
29 25 before and after coronary artery bypass grafting. *BMJ*. 1991;302:511-6.
30 26 11. Wenger NK, Froelicher ES, Smith LK, Ades PA, Berra K, Blumenthal JA, Certo CM,
31 27 Dattilo AM, Davis D, DeBusk RF and et al. Cardiac rehabilitation as secondary prevention.
32 28 Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. *Clin*
33 29 *Pract Guidel Quick Ref Guide Clin*. 1995:1-23.
34 30 12. Chocron S, Etievent JP, Viel JF, Dussaucy A, Clement F, Alwan K, Neidhardt M and
35 31 Schipman N. Prospective study of quality of life before and after open heart operations. *Ann*
36 32 *Thorac Surg*. 1996;61:153-7.
37 33 13. Siminoff LA. Incorporating patient and family preferences into evidence-based medicine.
38 34 *BMC medical informatics and decision making*. 2013;13 Suppl 3:S6.
39 35 14. Bensing J. Bridging the gap. The separate worlds of evidence-based medicine and
40 36 patient-centered medicine. *Patient Educ Couns*. 2000;39:17-25.
41 37 15. Torgerson DJ and Sibbald B. Understanding controlled trials. What is a patient
42 38 preference trial? *BMJ*. 1998;316:360.
43 39 16. Sun L.Y. TJV, Lee D.S., Beanlands R.S., Ruel M., Austin P.C., Bader Eddeen A., Liu
44 40 P.P. Disability-Free Survival After Coronary Artery Bypass Grafting in Women and Men with
45 41 Heart Failure. *BMJ Open Heart*. 2018;5:e000911.
46 42 17. Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov
47 43 MO, Margolis HS and Bell BP. Hepatitis A vaccine versus immune globulin for postexposure
48 44 prophylaxis. *The New England journal of medicine*. 2007;357:1685-94.
49
50
51
52
53
54
55
56
57
58
59
60

- 1 18. Tu JV, Ko DT, Guo H, Richards JA, Walton N, Natarajan MK, Wijeyesundera HC, So D,
2 Latter DA, Feindel CM, Kingsbury K, Cohen EA and Cardiac Care Network of Ontario's
3 Variations in Revascularization Practice in Ontario Working G. Determinants of variations in
4 coronary revascularization practices. *CMAJ*. 2012;184:179-86.
- 5 19. Tu K, Campbell NRC, Chen ZL, Cauch-Dudek KJ and McAlister FA. Accuracy of
6 administrative databases in identifying patients with hypertension. *Open Medicine*. 2007;1.
- 7 20. Juurlink D, Preya C, Croxford R, Chong A, Austin P, Tu J and Laupacis A. *Canadian
8 Institute for Health Information Discharge Abstract Database: A Validation Study. ICES
9 Investigative Report*. Toronto, ON: Institute for Clinical Evaluative Sciences; 2006.
- 10 21. Hux JE, Ivis F, Flintoft V and Bica A. Diabetes in Ontario: determination of prevalence
11 and incidence using a validated administrative data algorithm. *Diabetes Care*. 2002;25.
- 12 22. Austin PC, Daly PA and Tu JV. A multicenter study of the coding accuracy of hospital
13 discharge administrative data for patients admitted to cardiac care units in Ontario. *Am Heart J*.
14 2002;144.
- 15 23. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck
16 CA, Feasby TE and Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and
17 ICD-10 administrative data. *Med Care*. 2005;43.
- 18 24. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L and To T. Identifying
19 individuals with physician diagnosed COPD in health administrative databases. *COPD*. 2009;6.
- 20 25. Schultz SE, Rothwell DM, Chen Z and Tu K. Identifying cases of congestive heart failure
21 from administrative data: a validation study using primary care patient records. *Chronic Dis Inj
22 Can*. 2013;33:160-6.
- 23 26. Johnston A, Mesana TG, Lee DS, Eddeen AB and Sun LY. Sex Differences in Long-
24 Term Survival After Major Cardiac Surgery: A Population-Based Cohort Study. *J Am Heart
25 Assoc*. 2019;8:e013260.
- 26 27. du Plessis V, Beshiri R, Bollman RD and Clemeson H. *Definitions of "rural". Agriculture
27 and Rural Working Paper Series, No. 61*. Ottawa, ON: Statistics Canada; 2002.
- 28 28. Sun LYT, J. V.; Bader Eddeen, A.; Liu, P.P. Prevalence and Long-Term Survival After
29 Coronary Artery Bypass Grafting in Men and Women with Heart Failure and Preserved vs
30 Reduced Ejection Fraction. *JAHA*. 2018;7.
- 31 29. Tran DTT, Tu JV, Dupuis JY, Bader Eddeen A and Sun LY. Association of Frailty and
32 Long-Term Survival in Patients Undergoing Coronary Artery Bypass Grafting. *J Am Heart
33 Assoc*. 2018;7.
- 34 30. Lieberman R AC, Weiner J. Development and evaluation of the Johns Hopkins
35 University Risk Adjustment Models for Medicare+ Choice Plan Payment. 2003.
- 36 31. Sternberg SA, Bentur N, Abrams C, Spalter T, Karpati T, Lemberger J and Heymann
37 AD. Identifying frail older people using predictive modeling. *Am J Manag Care*. 2012;18:e392-
38 7.
- 39 32. The Johns Hopkins Adjusted Clinical Groups Technical Reference Guide, version 9.0.
40 2009.
- 41 33. Bronskill S CM, Costa A, et al. Aging in Ontario: An ICES Chartbook of Health Services
42 Use by Older Adults - a Technical Report. 2010.
- 43 34. Bronskill S CX, Gruneir A, Ho M. Health system use by frail Ontario seniors: an in-depth
44 examination of four vulnerable cohorts. 2011.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 35. Tu K, Wang M, Young J, Green D, Ivers NM, Butt D, Jaakkimainen L and Kapral MK. Validity of administrative data for identifying patients who have had a stroke or transient ischemic attack using EMRALD as a reference standard. *Can J Cardiol.* 2013;29:1388-94.
 - 2 36. Frank L, Basch E, Selby JV and Patient-Centered Outcomes Research I. The PCORI perspective on patient-centered outcomes research. *Jama.* 2014;312:1513-4.
 - 3 37. Macario A, Weinger M, Carney S and Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. *Anesth Analg.* 1999;89:652-8.
 - 4 38. Eberhart LH, Morin AM, Wulf H and Geldner G. Patient preferences for immediate postoperative recovery. *British journal of anaesthesia.* 2002;89:760-1.
 - 5 39. Rashid S and Bray P. Relative value to surgical patients and anesthesia providers of selected anesthesia related outcomes. *BMC medical informatics and decision making.* 2003;3:3.
 - 6 40. McNamara RL, Spatz ES, Kelley TA, Stowell CJ, Beltrame J, Heidenreich P, Tresserras R, Jernberg T, Chua T, Morgan L, Panigrahi B, Rosas Ruiz A, Rumsfeld JS, Sadwin L, Schoeberl M, Shahian D, Weston C, Yeh R and Lewin J. Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). *J Am Heart Assoc.* 2015;4.
 - 7 41. Revicki DA. Patient assessment of treatment satisfaction: methods and practical issues. *Gut.* 2004;53 Suppl 4:iv40-4.
 - 8 42. Ferguson TB, Jr., Hammill BG, Peterson ED, DeLong ER, Grover FL and Committee STSND. A decade of change--risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. *Ann Thorac Surg.* 2002;73:480-9; discussion 489-90.
 - 9 43. Sun L.Y. CAM, Farkouh M., Van Diepen S., Weinberger J., Bourke M., Ruel M. Defining a Perioperative Hypotension Threshold in Association with Stroke in Cardiac Surgery. *Anesthesiology.* 2018;In press.
 - 10 44. Taghipour HR, Naseri MH, Safiarian R, Dadjoo Y, Pishgoo B, Mohebbi HA, Daftari Besheli L, Malekzadeh M and Kabir A. Quality of life one year after coronary artery bypass graft surgery. *Iran Red Crescent Med J.* 2011;13:171-7.
 - 11 45. Gjeilo KH, Wahba A, Klepstad P, Lydersen S and Stenseth R. Survival and quality of life in an elderly cardiac surgery population: 5-year follow-up. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.* 2013;44:e182-8.
 - 12 46. Caceres M, Cheng W, De Robertis M, Mirocha JM, Czer L, Esmailian F, Khoynzhad A, Ramzy D, Kass R and Trento A. Survival and quality of life for nonagenarians after cardiac surgery. *Ann Thorac Surg.* 2013;95:1598-602.

1
2
3 **1 FIGURES**
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



15 **Figure 1.** Cumulative incidence of disability within one year after cardiac surgery.




Figure 2. Estimated survival within one year after cardiac surgery.

1 **Table 1. Baseline characteristics, stratified by type of surgery**

Variable	No. (%) of patients*						P value
	Overall	Isolated	Single	Multiple	CABG +	CABG +	
	population	CABG	valve†	valves‡	single valve†	multiple valves‡	
	(N=72 824)	(N= 52 546)	(N= 10 368)	(N= 1 309)	(N= 7 936)	(N= 665)	
Age, mean ± SD, y	67.0 ± 10.2	65.9 ± 9.8	67.5 ± 11.2	68.3 ± 11.4	72.6 ± 9.0	72.5 ± 9.1	<0.001
40-64	28 941 (39.7)	22 925 (43.6)	3 969 (38.3)	458 (35.0)	1 460 (18.4)	129 (19.4)	<0.001
65-74	25 229 (34.6)	18 626 (35.4)	3 197 (30.8)	395 (30.2)	2 795 (35.2)	216 (32.5)	
75-84	16 806 (23.1)	10 220 (19.4)	2 801 (27.0)	388 (29.6)	3 128 (39.4)	269 (40.5)	
≥85	1 848 (2.5)	775 (1.5)	401 (3.9)	68 (5.2)	553 (7.0)	51 (7.7)	
Rural Residence	11 763 (16.2)	8 204 (15.6)	1 756 (16.9)	203 (15.5)	1 457 (18.4)	143 (21.5)	
Income quintile							
1 (lowest)	13 448 (18.5)	10 003 (19.0)	1 728 (16.7)	245 (18.7)	1 370 (17.3)	102 (15.3)	<0.001
2	14 696 (20.2)	10 724 (20.4)	1 959 (18.9)	257 (19.6)	1 608 (20.3)	148 (22.3)	
3	14 759 (20.3)	10 627 (20.2)	2 117 (20.4)	249 (19.0)	1 609 (20.3)	157 (23.6)	

4	15 017 (20.6)	10 714 (20.4)	2 214 (21.4)	257 (19.6)	1 705 (21.5)	127 (19.1)	
5 (highest)	14 532 (20.0)	10 184 (19.4)	2 310 (22.3)	292 (22.3)	1 617 (20.4)	129 (19.4)	
Missing	372 (0.5)	294 (0.6)	40 (0.4)	9 (0.7)	27 (0.3)	≤5	
Hypertension	62 852 (86.3)	46 111 (87.8)	7 954 (76.7)	1 007 (76.9)	7 185 (90.5)	595 (89.5)	<0.001
Atrial fibrillation	5 165 (7.1)	2 373 (4.5)	1 343 (13.0)	304 (23.2)	990 (12.5)	155 (23.3)	<0.001
Recent MI	22 952 (31.5)	20 684 (39.4)	422 (4.1)	55 (4.2)	1 659 (20.9)	132 (19.8)	<0.001
Remote MI	11 605 (15.9)	9 432 (17.9)	679 (6.5)	91 (7.0)	1 295 (16.3)	108 (16.2)	<0.001
Previous PCI	10 532 (14.5)	8 773 (16.7)	617 (6.0)	70 (5.3)	1 004 (12.7)	68 (10.2)	<0.001
Heart failure	19 847 (27.3)	10 126 (19.3)	4 729 (45.6)	848 (64.8)	3 714 (46.8)	430 (64.7)	<0.001
LVEF							
≥50%	48 185 (66.2)	32 237 (61.4)	8 843 (85.3)	1 040 (79.4)	5 630 (70.9)	435 (65.4)	
35-50%	15 448 (21.2)	12 762 (24.3)	967 (9.3)	176 (13.4)	1 398 (17.6)	145 (21.8)	
20-35%	6 044 (8.3)	4 911 (9.3)	346 (3.3)	67 (5.1)	654 (8.2)	66 (9.9)	
<20%	1 113 (1.5)	905 (1.7)	43 (0.4)	13 (1.0)	139 (1.8)	13 (2.0)	
Missing	2 034 (2.8)	1 731 (3.3)	169 (1.6)	13 (1.0)	115 (1.4)	6 (0.9)	<0.001
Cerebrovascular	7 420 (10.2)	5 132 (9.8)	970 (9.4)	163 (12.5)	1 073 (13.5)	82 (12.3)	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

disease							
Peripheral arterial disease	9 139 (12.5)	6 424 (12.2)	1 079 (10.4)	139 (10.6)	1 389 (17.5)	108 (16.2)	<0.001
COPD or asthma	21 419 (29.4)	14 702 (28.0)	3 301 (31.8)	439 (33.5)	2 726 (34.3)	251 (37.7)	<0.001
Diabetes mellitus	32 812 (45.1)	25 267 (48.1)	3 218 (31.0)	422 (32.2)	3 639 (45.9)	266 (40.0)	<0.001
Morbid obesity	28 391 (39.0)	20 490 (39.0)	3 951 (38.1)	563 (43.0)	3 106 (39.1)	281 (42.3)	0.004
Hypothyroidism	1 419 (1.9)	969 (1.8)	206 (2.0)	40 (3.1)	186 (2.3)	18 (2.7)	<0.001
Liver disease	633 (0.9)	351 (0.7)	153 (1.5)	37 (2.8)	81 (1.0)	11 (1.7)	<0.001
Anemia	7 347 (10.1)	4 918 (9.4)	977 (9.4)	203 (15.5)	1 113 (14.0)	136 (20.5)	<0.001
Venous thromboembolism	288 (0.4)	173 (0.3)	57 (0.5)	10 (0.8)	46 (0.6)	≤5	<0.001
Dialysis	1 531 (2.1)	1 047 (2.0)	195 (1.9)	34 (2.6)	233 (2.9)	22 (3.3)	<0.001
Baseline Creatinine (μmol/L)							
120-179	6 635 (9.1)	4 487 (8.5)	855 (8.2)	163 (12.5)	1 037 (13.1)	93 (14.0)	<0.001
<120	60 190 (82.7)	43 934 (83.6)	8 538 (82.3)	1 038 (79.3)	6 158 (77.6)	522 (78.5)	

≥ 180	2 435 (3.3)	1 698 (3.2)	261 (2.5)	63 (4.8)	381 (4.8)	32 (4.8)	
Missing	3 564 (4.9)	2 427 (4.6)	714 (6.9)	45 (3.4)	360 (4.5)	18 (2.7)	
Chronic renal disease	3 133 (4.3)	2 109 (4.0)	399 (3.8)	66 (5.0)	516 (6.5)	43 (6.5)	<0.001
Dementia	176 (0.2)	98 (0.2)	27 (0.3)	≤5	41 (0.5)	6 (0.9)	<0.001
Depression	1 089 (1.5)	733 (1.4)	157 (1.5)	37 (2.8)	149 (1.9)	13 (2.0)	<0.001
Psychosis	161 (0.2)	102 (0.2)	33 (0.3)	6 (0.5)	17 (0.2)	≤5	0.025
Primary tumor	3 770 (5.2)	2 486 (4.7)	601 (5.8)	96 (7.3)	539 (6.8)	48 (7.2)	<0.001
Metastatic cancer	375 (0.5)	248 (0.5)	72 (0.7)	10 (0.8)	40 (0.5)	≤5	0.03
Charlson score, median (IQR)	1 (0-3)	2 (0-3)	1 (0-2)	1 (0-2)	2 (0-3)	2 (1-3)	<0.001
Frailty [§]	11 685 (16.0)	8 623 (16.4)	1 204 (11.6)	213 (16.3)	1 491 (18.8)	154 (23.2)	<0.001

1 * Unless otherwise stated †Mitral, aortic or tricuspid valve surgery ‡Mitral, aortic or tricuspid valve surgery

2 §According to the Johns Hopkins Adjusted Clinical Groups frailty-defining diagnoses indicator²⁹⁻³⁴

3 Abbreviations: CABG = coronary artery bypass grafting; COPD = chronic obstructive pulmonary disease; LVEF = left ventricular
4 ejection fraction; MI = myocardial infarction; PCI = percutaneous coronary intervention; IQR = interquartile range

1
2
3 **Table 2.** Event rates within 1 year following cardiac surgery.
4

Event, n (%)	CABG (n=52,546)	Single Valve (n=10,368)	Multiple Valves (n=1,309)	CABG + Single Valve (n=7,936)	CABG + Multiple Valves (n=665)	P-Value
Disability	2,431 (4.6)	677 (6.5)	118 (9.0)	718 (9.1)	87 (13.1)	<0.001
Death	1,839 (3.5)	540 (5.2)	140 (10.7)	734 (9.2)	94 (14.1)	<0.001
Stroke	808 (1.5)	258 (2.5)	48 (3.7)	280 (3.5)	38 (5.7)	<0.001
≥ 3 non-elective hospitalizations	1,454 (2.8)	367 (3.5)	57 (4.4)	373 (4.7)	41 (6.2)	<0.001
Long-term care admission	342 (0.7)	102 (1.0)	20 (1.5)	122 (1.5)	12 (1.8)	<0.001

Abbreviations: CABG = coronary artery bypass grafting

2

1 **Table 3.** Multivariable predictors of disability at one-year after major cardiac surgery.

Variable	HR (95% CI)	P-Value
Age	1.03 (1.02-1.03)	<0.001
Female	1.38 (1.28-1.48)	<0.001
Surgery Type		
Isolated CABG	Reference	Reference
Single Valve	1.34 (1.21-1.48)	<0.001
Multiple Valves	1.43 (1.18-1.75)	<0.001
CABG + Single Valve	1.38 (1.26-1.51)	<0.001
CABG + Multiple Valves	1.78 (1.43-2.23)	<0.001
Emergent Procedure	1.40 (1.26-1.57)	<0.001
Rural Residence	1.03 (0.94-1.12)	0.55
Income Quintile		
1 (Lowest)	1.33 (1.20-1.47)	<0.001
2	1.16 (1.05-1.29)	0.004
3	1.11 (1.00-1.23)	0.05
4	0.99 (0.89-1.10)	0.83
5 (Highest)	Reference	Reference
Hypertension	1.16 (1.03-1.31)	0.02
Atrial Fibrillation	1.25 (1.14-1.37)	<0.001
Heart Failure	1.66 (1.53-1.79)	<0.001
MI within 30 Days	1.26 (1.17-1.36)	<0.001
Remote MI	1.13 (1.04-1.23)	<0.001
Previous PCI	0.94 (0.85-1.03)	0.17
LVEF		
< 20%	1.10 (0.89-1.36)	0.37
20-34%	1.07 (0.99-1.16)	0.10
35-49%	1.00 (0.89-1.11)	0.94
≥ 50%	Reference	Reference
Cerebrovascular Disease	1.40 (1.29-1.53)	<0.001
Peripheral Arterial Disease	1.23 (1.14-1.34)	<0.001
Smoker		
Never	Reference	Reference
Current	1.19 (1.09-1.30)	<0.001
Former	1.07 (0.99-1.15)	0.08
COPD/Asthma	1.32 (1.24-1.41)	<0.001
Pulmonary Circlatory Disorder	1.07 (0.91-1.24)	0.42
Morbid Obesity	0.97 (0.91-1.03)	0.31

Diabetes	1.38 (1.29-1.47)	<0.001
Hypothyroidism	1.10 (0.93-1.31)	0.25
Anemia	1.39 (1.28-1.51)	<0.001
Baseline Creatinine ($\mu\text{mol/L}$)		
< 120	Reference	Reference
120-179	1.32 (1.21-1.45)	<0.001
≥ 180	1.81 (1.57-2.08)	<0.001
Dialysis	1.40 (1.19-1.64)	<0.001
Liver Disease	1.33 (1.06-1.68)	0.02
Alcoholism	1.68 (1.39-2.03)	<0.001
Dementia	1.59 (1.13-2.24)	0.01
Depression	1.66 (1.41-1.97)	<0.001
Psychosis	1.05 (0.62-1.76)	0.87
Primary Cancer	1.19 (1.06-1.34)	0.004
Metastatic Cancer	1.47 (1.08-1.99)	0.01

1

2 Abbreviations: CABG = coronary artery bypass grafting; MI = myocardial infarction; PCI =
 3 percutaneous coronary intervention; COPD = chronic obstructive pulmonary disease; HR =
 4 hazard ratio, CI = confidence interval

5

Supplemental Material

Supplemental Figure 1. Cohort selection flow chart

Supplemental Figure 2. Cumulative incidence of stroke within one year after cardiac surgery.


Supplemental Figure 3. Cumulative incidence of long-term care (LTC) admissions within one year after cardiac surgery.

Supplemental Figure 4. Cumulative incidence of recurrent non-elective hospitalizations (≥ 3 episodes per year) within one year after cardiac surgery.

Confidential


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental Figure 1. Cohort selection flow chart




Abbreviation: CABG = coronary artery bypass surgery

Supplemental Figure 2. Cumulative incidence of stroke within one year after cardiac surgery.




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental Figure 3. Cumulative incidence of long-term care (LTC) admissions within one year after cardiac surgery.



Supplemental Figure 4. Cumulative incidence of recurrent non-elective hospitalizations (≥ 3 episodes per year) within one year after cardiac surgery.



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title page 1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	3 N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3-4
Bias	9	Describe any efforts to address potential sources of bias	5-6
Study size	10	Explain how the study size was arrived at	3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	5-6
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Suppl Fig 1 Suppl Fig 1 Suppl Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	7 Table 1 5
Outcome data	15*	Report numbers of outcome events or summary measures over time	Table 2; p.7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	p. 8; Table 3
2			(b) Report category boundaries when continuous variables were categorized	Table 1
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6-7
5	Discussion			
6	Key results	18	Summarise key results with reference to study objectives	9
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
10	Other information			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Title page

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.